Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report)'s stock price shot up 4.7% during trading on Friday . The stock traded as high as $2.11 and last traded at $2.11. 257,954 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 2,318,294 shares. The stock had previously closed at $2.01.
Wall Street Analysts Forecast Growth
A number of research firms have issued reports on MRVI. Robert W. Baird decreased their target price on Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Stifel Nicolaus set a $5.00 price objective on Maravai LifeSciences in a research report on Friday, March 21st. UBS Group dropped their target price on shares of Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating on the stock in a report on Friday, March 21st. Morgan Stanley cut their price target on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating on the stock in a research note on Tuesday, March 25th. Finally, Bank of America cut their price target on Maravai LifeSciences from $9.00 to $8.00 and set a "buy" rating on the stock in a report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Maravai LifeSciences presently has a consensus rating of "Hold" and an average target price of $6.64.
Get Our Latest Research Report on Maravai LifeSciences
Maravai LifeSciences Stock Performance
The stock has a 50 day moving average of $2.09 and a 200 day moving average of $3.43. The firm has a market cap of $525.87 million, a price-to-earnings ratio of -1.81 and a beta of 0.25. The company has a quick ratio of 5.17, a current ratio of 5.96 and a debt-to-equity ratio of 0.60.
Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The firm had revenue of $46.85 million for the quarter, compared to analyst estimates of $44.01 million. Maravai LifeSciences had a negative net margin of 67.14% and a negative return on equity of 12.91%. The business's quarterly revenue was down 26.9% compared to the same quarter last year. As a group, analysts anticipate that Maravai LifeSciences Holdings, Inc. will post -0.24 EPS for the current fiscal year.
Institutional Trading of Maravai LifeSciences
Large investors have recently bought and sold shares of the business. Empowered Funds LLC bought a new position in shares of Maravai LifeSciences in the fourth quarter worth about $155,000. Rhumbline Advisers increased its holdings in shares of Maravai LifeSciences by 9.9% during the fourth quarter. Rhumbline Advisers now owns 185,221 shares of the company's stock worth $1,009,000 after buying an additional 16,712 shares in the last quarter. Y Intercept Hong Kong Ltd lifted its stake in shares of Maravai LifeSciences by 155.9% in the 4th quarter. Y Intercept Hong Kong Ltd now owns 32,359 shares of the company's stock valued at $176,000 after acquiring an additional 19,713 shares during the last quarter. VELA Investment Management LLC boosted its holdings in shares of Maravai LifeSciences by 54.5% during the 4th quarter. VELA Investment Management LLC now owns 148,112 shares of the company's stock valued at $807,000 after acquiring an additional 52,246 shares in the last quarter. Finally, Victory Capital Management Inc. grew its position in Maravai LifeSciences by 65.1% during the 4th quarter. Victory Capital Management Inc. now owns 96,273 shares of the company's stock worth $525,000 after acquiring an additional 37,946 shares during the last quarter. 50.25% of the stock is owned by institutional investors and hedge funds.
Maravai LifeSciences Company Profile
(
Get Free Report)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Maravai LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list.
While Maravai LifeSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
